WALTHAM, Mass., April 22, 2026 – Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases, today announced the selection of an abstract for presentation in a poster session at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting will take place from May 29 to June 2 in Chicago, IL.
Presentation details are below:
Poster Title: SARM1 Inhibition to Prevent Chemotherapy-Induced Peripheral Neuropathy: Translational and Early Clinical Evaluation of SIR2501
Poster Board: 131
Abstract #: 12148
Date/Time: May 30, 2026, 1:30-4:30 PM CDT
About Sironax
Headquartered in Waltham, Massachusetts, Sironax is a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases. The company has built a diverse pipeline of programs by targeting contributors of aging: degeneration, metabolic dysfunction, and inflammation. In addition to NAMPT activator SIR4156, Sironax is conducting clinical studies with SARM1 inhibitor SIR2501 and RIPK1 inhibitor SIR9900, as well as ongoing preclinical research. The company was recently named to Fierce Biotech’s “Fierce 15” list of the most innovative and promising private biotechs of 2026. For more information, visit sironax.com.